Last month, Bristol Myers Squibb's (NYSE: BMY) chimeric antigen receptor (CAR) T cell therapy, known as Breyanzi, was given the green light to be marketed in Japan as a the second-line treatment for relapsed or refractory large B-cell lymphoma.

This regulatory decision raises two key questions. What is the data behind Japan's approval of Breyanzi? And how much revenue could the therapy produce for the pharmaceutical company? Let's dive into Breyanzi's phase 3 clinical trial results and the Japanese lymphoma market to answer these questions. 

Lymphoma is a cancer that affects the lymphatic system. This system is responsible for guarding the body against infections, eliminating cellular waste, and maintaining body fluid levels. The symptoms of lymphoma include itchy skin, fatigue, shortness of breath, and unintentional weight loss. 

Continue reading

Source Fool.com